NEW YORK – The UK's National Institute for Health and Care Excellence on Tuesday recommended Bristol Myers Squibb's immunotherapy combination Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line ...

The firms will explore molecular mechanisms and patient responses in cancer to inform development of new therapies.

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.